[{"id":"45785a07-9d38-4987-a49f-4d7f22463b54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188664","created_at":"2022-01-12T14:53:34.539Z","updated_at":"2025-02-25T14:08:34.404Z","phase":"Phase 1/2","brief_title":"Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05188664","lead_sponsor":"LaNova Australia Pty Limited","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 11/14/2023","primary_completion_date":" 11/14/2023","study_txt":" Completion: 11/14/2023","study_completion_date":" 11/14/2023","last_update_posted":"2025-02-17"},{"id":"56340f92-11bf-404d-bdf4-c92c67bb6993","acronym":"","url":"https://clinicaltrials.gov/study/NCT05001516","created_at":"2021-08-12T14:54:30.593Z","updated_at":"2024-07-02T16:35:09.043Z","phase":"Phase 1","brief_title":"Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05001516","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MSI • CLDN18","pipe":" | ","alterations":" MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive","tags":["MSI • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/29/2021","start_date":" 12/29/2021","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2024","study_completion_date":" 01/04/2024","last_update_posted":"2024-04-17"},{"id":"85e7121a-617b-4471-a40e-31d0ee93b7df","acronym":"","url":"https://clinicaltrials.gov/study/NCT05161390","created_at":"2021-12-17T17:31:06.701Z","updated_at":"2024-07-02T16:35:09.258Z","phase":"Phase 1/2","brief_title":"Study of LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05161390","lead_sponsor":"LaNova Medicines Zhejiang Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 206","initiation":"Initiation: 11/26/2021","start_date":" 11/26/2021","primary_txt":" Primary completion: 03/10/2025","primary_completion_date":" 03/10/2025","study_txt":" Completion: 06/08/2025","study_completion_date":" 06/08/2025","last_update_posted":"2024-04-17"},{"id":"96bebf64-22cc-44fe-8eb7-2b3fcb1d55b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05934331","created_at":"2023-07-06T16:10:33.332Z","updated_at":"2024-07-02T16:35:34.327Z","phase":"Phase 2","brief_title":"A LM-302 Combined With Toripalimab Phase II Study","source_id_and_acronym":"NCT05934331","lead_sponsor":"LaNova Medicines Zhejiang Co., Ltd.","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-10-06"}]